NeuroNexus is a fast-growing neurotechnology company that develops and commercializes high-value neural interface technologies, instrumentation systems, and analytics and visualization software for neuroscience and clinical applications. NeuroNexus is known for innovative, professional-grade devices, systems, and tools to empower discovery in the life sciences.
NeuroNexus’ platform technologies have spawned dozens of innovative products to enable leading-edge research in thousands of labs all around the world. Our products include a broad range of thin-film neural probes and electrode arrays, instrumentation systems for electrophysiological recording and stimulation, and data analytics and visualization software. Our products are used across a wide variety of applications from scientific investigations of neural circuits of insects to developing powerful, next-generation diagnostics and functional therapies for significant indications in neurology and cardiology.
NeuroNexus is based in Ann Arbor, Michigan, USA, with operations in Boston, Massachusetts and Dallas, Texas. NeuroNexus is the operating company of the NEL Group, Inc.
About NEL Group, Inc.
The NEL Group, Inc. is an independent, privately held investment company focused on emerging opportunities in neuromodulation, neuroscience, cardiology, and the life sciences. Through its small number of knowledgeable private investors and NeuroNexus, its well-established operating company, the NEL Group has an expanding intellectual property portfolio in neurotechnology and an extensive professional network across med-tech, biomedical engineering and the life sciences. The NEL Group has interests in developing and commercializing highly advanced implantable devices for interfacing with the brain, neuroaxis, and heart for neuromodulation, cardiology, bioelectronic medicine, and scientific discovery. The NEL Group is based in Ann Arbor, Michigan, USA and is led by Dr. Daryl Kipke, CEO and Managing Director.